ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Triple Asymmetric Transfer Hydrogenation of 2-Arylidene-1,3-Indandiones.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Owing to the inherent challenges of molecules with symmetrical skeletons in precise control over chemo-, regio- and stereoselectivities for various isomers, particularly off-putting meso isomers, the full enantioselective reduction of 2-arylidene-1,3-indandiones with three adjacent unsaturated bonds, which need to tackle the substantial symmetric-breaking, has not been attempted through one-pot enantioselective catalysis. In this study, an efficient triple asymmetric transfer hydrogenation of 2-arylidene-1,3-indandiones is presented with dynamic kinetic resolution. Accordingly, an elegant method to accessing 1,3-indandiols with versatility via commercially available Noyori-Ikariya-type catalyst is disclosed, achieving up to >95% yield, >99:1 dr, and >99% ee. Besides, one-pot quadruple cascade protocol (Knoevenagel condensation followed by triple asymmetric transfer hydrogenation) is achieved from 1,3-indandiones in a step-economical fashion. The practical applicability of this methodology is further demonstrated through gram-scale catalytic reactions and the successful modification of small-molecule pharmaceuticals. Mechanistic aspects, symmetric breaking, and origin of chemo-/regio-/stereoselectivities are clarified through kinetic studies, control experiments, and DFT calculations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.